Meeting
2023 ASCO Annual Meeting
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
Authors
Uday R. Popat
Department of Stem Cell Transplantation & Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX
Uday R. Popat , Konstantinos Lontos , Roland L. Bassett Jr., Amin Majid Alousi , Gheath Alatrash , Qaiser Bashir , Chitra M. Hosing , Jin Seon Im , Partow Kebriaei , David Marin , Rohtesh S. Mehta , Yago Nieto , Betul Oran , Amanda Leigh Olson , Muzaffar H. Qazilbash , Jeremy L Ramdial , Samer Ali Srour , Elizabeth J. Shpall , Richard E. Champlin , Borje S Andersson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Allogenic Stem Cell Transplantation
Clinical Trial Registration Number
NCT02250937
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7051)
DOI
10.1200/JCO.2023.41.16_suppl.7051
Abstract #
7051
Poster Bd #
181
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome.
First Author: Henry Jacob Conter
Poster
2011 ASCO Annual Meeting
A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.
First Author: S. Kim
Poster
2021 ASCO Annual Meeting
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
First Author: Katherine Tarlock
Poster
2011 ASCO Annual Meeting
Survival after nonmyeloablative versus myeloablative allotransplantation for AML/MDS.
First Author: M. R. Khawaja